Gary S. Francis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gary S. Francis has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
W.H.Wilson Tang
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
2 shared publicationsA. Kanderian
Department of Cardiovascular Medicine, Cleveland Clinic-desk F15, Cleveland, Ohio, USA
1 shared publicationJames B. Young
1 shared publicationW.H. Wilson Tang
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
1 shared publication
Latest Publications
- Open Access
- 1 September 2008
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 1 (3) , 208-209
The Contemporary Use of Digoxin for the Treatment of Heart Failure
T he use of digitalis has been plagued by controversy since its initial use by Withering in 1775. We now have much more data, 1 but it should be remembered that the Digitalis Investigator Group trial was executed when -blockers were not widely used to treat heart failure. There are still many questions about where we currently stand with the use of digitalis. Specifically, when should one add digoxin to the medical regimen of a patient with heart failure symptoms? Another question that frequently arises is whether one should consider stopping digoxin in a patient referred for care who has chronic stable heart failure. I will briefly examine these 2 scenarios separately. Should One Discontinue Digoxin in a Patient With Stable Heart Failure? One should never thoughtlessly change therapy in patients who are doing well. In fact, I have tended to avoid requesting such The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
- 1 September 2008
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 1 (3) , 208-209
Open AccessThe Contemporary Use of Digoxin for the Treatment of Heart Failure
T he use of digitalis has been plagued by controversy since its initial use by Withering in 1775. We now have much more data, 1 but it should be remembered that the Digitalis Investigator Group trial was executed when -blockers were not widely used to treat heart failure. There are still many questions about where we currently stand with the use of digitalis. Specifically, when should one add digoxin to the medical regimen of a patient with heart failure symptoms? Another question that frequently arises is whether one should consider stopping digoxin in a patient referred for care who has chronic stable heart failure. I will briefly examine these 2 scenarios separately. Should One Discontinue Digoxin in a Patient With Stable Heart Failure? One should never thoughtlessly change therapy in patients who are doing well. In fact, I have tended to avoid requesting such The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
- 1 October 2006
- Published by Elsevier in Kidney International
- Vol. 70 (8) , 1526
Response to ‘Cardiac troponins and chronic kidney disease’
- 1 October 2006
- Published by Elsevier in Kidney International
- Vol. 70 (8) , 1526
Response to ‘Cardiac troponins and chronic kidney disease’
- Open Access
- 1 June 2006
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 73 (Suppl_2) , S8
Acute decompensated heart failure: the cardiorenal syndrome.
The cardiorenal syndrome is not well understood, and a uniform definition is lacking. Worsening renal function as determined by a decline in creatinine clearance in patients with decompensated heart failure is an identifier of patients with this syndrome. Treatment is a challenge. Diuretic therapy is valuable in treating congestion but may worsen renal function. Patients with decompensated heart failure are often refractory to diuretics, in which case higher doses must be used or alternate methods explored to reduce salt and water.
- 1 June 2006
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 73 (Suppl_2) , S8
Open AccessAcute decompensated heart failure: the cardiorenal syndrome.
The cardiorenal syndrome is not well understood, and a uniform definition is lacking. Worsening renal function as determined by a decline in creatinine clearance in patients with decompensated heart failure is an identifier of patients with this syndrome. Treatment is a challenge. Diuretic therapy is valuable in treating congestion but may worsen renal function. Patients with decompensated heart failure are often refractory to diuretics, in which case higher doses must be used or alternate methods explored to reduce salt and water.
Should we consider aldosterone as the primary screening target for preventing cardiovascular events?
- 1 November 2004
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 47 (3) , 196-206
Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions
- 1 November 2004
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 47 (3) , 196-206
Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions
- 1 November 2001
- Published by Elsevier in Cardiology Clinics
- Vol. 19 (4) , 541-546
THE LOOMING POLYPHAMACY CRISIS IN THE MANAGEMENT OF PATIENTS WITH HEART FAILURE
- 1 November 2001
- Published by Elsevier in Cardiology Clinics
- Vol. 19 (4) , 541-546
THE LOOMING POLYPHAMACY CRISIS IN THE MANAGEMENT OF PATIENTS WITH HEART FAILURE
- Open Access
Diabetic cardiomyopathy: fact or fiction?
- 1 August 2000
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 67 (8) , 574-576
Fibrinolytic therapy in the elderly: making sense of troubling new findings.
- 1 August 2000
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 67 (8) , 574-576
Fibrinolytic therapy in the elderly: making sense of troubling new findings.